Submit RFI/RFP
Category

Uncategorized

Ramune Rukiene, MSc, Director Regulatory Affairs at Biomapas

CMC: Best Practice in Effective IND and IMPD writing

By | Uncategorized

This time we will focus on technical writing and preparation for it. Also, I will provide some primary recommendations for CMC writers. The IND/IMPD being a regulatory document, has the same structure as CTD dossier. However, it includes remarkably less information on the developmental product, yet, the technical writers should understand that they will need to prepare the document in the way to reflect the actual production process and control further during the development in the later clinical phases.

Read More
Josefina Jakobsson, MSc Pharmacovigilance Specialist Biomapas

What is a Safety Signal?

By | news1, Uncategorized

Occasionally we see the information of a safety signal for medical product, but what does it really mean? We can describe the safety signal as an indication for new and significant safety-related data for a marketed product. The new data could indicate a new potentially causal association between an adverse event, beneficial response and a medical product, or a new aspect of causal association that was previously known. Usually, a signal will be relevant for all products with the same active ingredient, including the combination products. Further, let’s look more at the main steps of the safety signal management.

Read More